Achilles Tendon and Balance in Prediabetes

Eskisehir Osmangazi University

Status: Completed

Conditions: PreDiabetes

Treatments: Device: ultrasonography evaluation; Device: tetrax device evaluation

Study type: Observational

Funder types: Other

Identifiers

NCT06519396

Achilles

Details and patient eligibility

About

The aim was to evaluate the Achilles tendon size and static and dynamic balance, as well as the role of Achilles tendon on balance in prediabetes. A total of 96 patients were divided into three groups: 1)the control group, consisting of patients without diabetes; 2)the prediabetes group; 3)the diabetes mellitus group. Ultrasonographic measurements of Achilles tendon sizes were performed. Dynamic balance was assessed using the Berg Balance Scale, static balance was assessed.The Self-Leeds Assessment of Neuropathic Symptoms and Signs was utilized to identify neuropathic pain.

Full description

Background/Aims: There is a lack of studies that examine balance problems and Achilles tendon thickness in prediabetes, despite their common occurrence in diabetes. The aim was to evaluate the Achilles tendon size and static and dynamic balance, as well as the role of Achilles tendon on balance in prediabetic patients.

Methods: A total of 96 patients were divided into three groups: 1)the control group, consisting of patients without diabetes; 2)the prediabetes group; 3)the diabetes mellitus group. Ultrasonographic measurements of Achilles tendon sizes (thickness, width and area) were performed. Dynamic balance was assessed using the Berg Balance Scale, static balance (the Fall Index, Stability Indexes) was assessed using a Tetrax device. The Self-Leeds Assessment of Neuropathic Symptoms and Signs was utilized to identify neuropathic pain.

Enrollment: 90 patients

Sex: All

Ages: 40 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• being between 40 and 65 years old

Exclusion criteria

• extremity amputation
• vitamin B12 deficiency
• Type 1 Diabetes Mellitus
• prior exposure to neurotoxic agents
• peripheral neuropathy for reasons such as chronic kidney failure, liver failure, - hypothyroidism, hereditary and inflammatory peripheral neuropathies, neuromuscular diseases, malignancies
• anti-neuropathic drug usage
• radiculopathy
• nerve trauma or surgery
• vasculitis and autoimmune disorders
• peripheral vascular disease
• pregnancy
• vestibular and cerebellar problems
• history of lower extremity surgery
• presence of medication affecting balance
• history of alcoholism
• presence of visual impairment.

Trial design

90 participants in 3 patient groups

Control

Description:

Patients in the control group had FPG\< 100 mg/dl or 75g oral glucose tolerance test: second hour plasma glucose \<140mg/dl and HbA1c values \<5.7%.

Treatment:

Device: tetrax device evaluation

Device: ultrasonography evaluation

Prediabetes

Description:

The diagnosis of prediabetes was also confirmed through the patients' medical records. Patients with FPG 100-125 mg/dl or 75g oral glucose tolerance test: second hour plasma glucose 140-199 mg/dl and HbA1c values 5.7-6.4% was included in the prediabetes group.

Treatment:

Device: tetrax device evaluation

Device: ultrasonography evaluation

Diabetes

Description:

The diagnosis of Type 2 Diabetes was confirmed through the patients' medical records. Patients with FPG≥ 126mg/dl or 75g oral glucose tolerance test: second hour plasma glucose ≥200mg/dl and HbA1c ≥6.5% were included in the diabetes group.

Treatment:

Device: tetrax device evaluation

Device: ultrasonography evaluation